Hims & Hers Health, Inc. (HIMS)

From the record

Hims & Hers Health, Inc.'s filings since 2019 show 2 warning events of 2 kinds: a warning not to rely on past financial statements (8-K item 4.02, the latest 2021-05-04); an auditor change (8-K item 4.01, the latest 2021-01-26) (its current reports).

From the record

Hims & Hers Health, Inc.'s 7 filed years say what it did: revenue went from $83 million in fiscal 2019 to $2.3 billion in fiscal 2025, up 74.7% a year; it rose in 6 of 6 years; it never fell from a peak; net income was positive in 2 of 7 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Hims & Hers Health, Inc.'s diluted share count grew about 8.1% a year, and dividends and buybacks returned about 28% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 46 sales (45 under scheduled 10b5-1 plans) and 1 purchase of their own stock on the open market in the year to 2026-10-29, buying about $1 million (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Hims & Hers Health, Inc. earned about 24 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 80 cents per dollar of everything the company owns. Leverage: it owed about 75 cents per dollar of assets, and net share issuance: its share count grew 9.0% over the year (the filed statements).

From the record

Hims & Hers Health, Inc.'s standing among 9 graded names in its industry family: revenue of $2.3 billion in fiscal 2025 ranks in the top 25% by size; a net margin of 5.5% ranks in the top 28%; revenue growth of 64.5% a year over the last 3 filed years ranks in the top 6% (its annual reports).

From the record

Hims & Hers Health, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Dudum, Andrew (Chief Executive Officer, as filed), filing under that title since 2021-01-22, 5.8 years (top 12% of its family); the 16 officers and directors filing in the last fifteen months have been on the record a median of 4.2 years (top 37%); 11 officer or director changes were reported on Form 8-K since 2023-11-13, against the 16 people in charge now (top 50%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Hims & Hers Health, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $229 million against no long-term debt tagged leaves 10.6% of its assets as net cash, top 50% of its family; cash from operations less capital spending is 2.4% of revenue (top 50%); a gross margin of 73.8% (top 30%) (its annual report).

From the record

Hims & Hers Health, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 64.5% a year over the last three filed years against 74.7% over all 7, slowing (bottom 44% of its family); the newest year grew 59% (top 6%); capital spending grew 222.9% a year (top 6%) (its annual reports). Hims & Hers Health, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

From the record

Hims & Hers Health, Inc.'s newest year against its own record: revenue of $2.3 billion in fiscal 2025 came in 5% below the $2.5 billion its prior three years' pace pointed to (bottom 25% of its family); net income of $128 million against a prior three-year average of $12 million (top 8%); a net margin of 5.5% against -2.2% before (bottom 42%) (its annual reports).